Form 4: Replimune Group CEO Acquires Shares and Options

CEO of Replimune Group, Sushil Patel, reports acquisition of common stock and stock options.

Summary

• Sushil Patel, CEO of Replimune Group, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the acquisition of 166,667 shares of common stock through restricted stock units (RSUs) on April 1, 2025.
• These RSUs vest over time, with 25% vesting on May 15, 2026, and the remainder in three equal annual installments until May 15, 2029, contingent upon continuous service.
• Patel also acquired options to purchase 250,000 shares of common stock at an exercise price of $8.40 on April 1, 2025.
• 25% of these options vest on April 1, 2026, with the remainder vesting in 36 approximately equal monthly installments thereafter.
• Following these transactions, Patel beneficially owns 368,681 shares of common stock and options for 250,000 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports transactions by an insider, which can be viewed as a sign of confidence, but doesn't inherently indicate positive or negative performance.

Positives

• The CEO's acquisition of shares and options could be interpreted as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders.

Stakeholder Impact

• The transactions may influence investor sentiment regarding Replimune Group.

Key Dates

Keywords

Replimune Group, Sushil Patel, CEO, Form 4, Beneficial Ownership, Stock Options, RSUs, Vesting